Andreas Vogt

Andreas Vogt, Ph.D.
Associate Professor
Ph.D. in Pharmaceutical Chemistry, University of Hamburg
Vogt
Contact
W957 Biomedical Science Tower
200 Lothrop Street
Pittsburgh, Pennsylvania 15261
Phone: (412) 383-5856
Fax: (412) 648-9009
E-mail: avogt@pitt.edu
Website:
Research Summary

One of my current research interests is the expansion of HCS into multicellular organisms. It is becoming increasingly clear that better models of the in vivo milieu are needed to improve the discovery of new drug candidates. Zebrafish, C. elegans, and Drosophila in particular provide unique opportunities to discover novel potential therapeutics using functional assays in a living animal as a complement to cellular and tissue model approaches. Together with members in the Departments of Neurology, Developmental Biology, and the Graduate School of Public Health I have established methodology for zebrafish chemical screening, generated automated image analysis tools for quantification of reporter gene expression, and automated neurobehavioral assays in multiwell plate formats. Current discovery projects include cancer immunology, kidney and heart regeneration, and neurodegenerative diseases.

In my role as a member of the UPDDI leadership faculty at the University of Pittsburgh Drug Discovery Institute I aim to translate outstanding basic discoveries into novel therapeutics by providing advice and support on all aspects of the drug discovery process including target validation, assay development and high throughput screening, and by stimulating and facilitating new drug development applications to funding agencies.

Dr. Vogt is a member of the Editorial Board for SLAS Discovery.

Recent Publications

Chen F, Shi Q, Pei F, Vogt A, Porritt RA, Garcia G, Jr., Gomez AC, Cheng MH, Schurdak ME, Liu B, Chan SY, Arumugaswami V, Stern AM, Taylor DL, Arditi M, Bahar I. A systems-level study reveals host-targeted repurposable drugs against SARS-CoV-2 infection. Mol Syst Biol. 2021;17(8):e10239. PubMed PMID: 34339582. (open access) http://dx.doi.org/10.15252/msb.202110239

Vogt A., Eicher S., Myers T., Hrizo S., Vollmer L., A, Meyer EM., and Palladino MJ. A high content screening assay for small molecules that stabilize mutant triose phosphate isomerase (TPI) as treatments for TPI-deficiency. SLAS Discov. 2021 Jun24, Online ahead of print. PMID: 34167376; PMCID: NIHMS1704229.  https://doi.org/10.1177/24725552211018198

Chan L, Murakami M, Caeser R, Hurtz C , Kume K, Sadras T, Shojaee S, Hong C, Pölönen P, Nix M, Ugale A, Z Chen Z, Lee J-W , Cosgun N, Geng H, Chen C, Chen J, Vogt A , Heinäniemi M , Lohi O, Wiita A , Izraeli S, Graeber T, Weinstock D, and Müschen M. Signaling input from divergent pathways subverts malignant B-cell transformation. Nature 2020 Jul 22. doi: 10.1038/s41586-020-2513-4. Online ahead of print.

Nmezi B, Vollmer LL, Shun TY, Gough A, Rolyan H, Liu F, Jia Y, Padiath QS, Vogt A. Development and Optimization of a High-Content Analysis Platform to Identify Suppressors of Lamin B1 Overexpression as a Therapeutic Strategy for Autosomal Dominant Leukodystrophy. SLAS Discov. 2020 Apr 30; PMID: 32349647.

Saydmohammed M, Vollmer LL, Onuoha EO, Maskrey TS, Gibson G, Watkins SC, Wipf P, Vogt A, Tsang M. A High-Content Screen Reveals New Small-Molecule Enhancers of Ras/Mapk Signaling as Probes for Zebrafish Heart Development. Molecules. 2018;23(7). PMID: 29997348.

Hukriede N, Vogt A, de Caestecker M. Drug Discovery to Halt the Progression of Acute Kidney Injury to Chronic Kidney Disease: A Case for Phenotypic Drug Discovery in Acute Kidney Injury. Nephron. 2017. doi: 10.1159/000476079. PMID: 28614822.

 

Grants
Project title Proj Start Date Proj End Date Funding Source
High-content screening for modulators of lamin B1 as a therapeutic target in autosomal dominant leukodystrophy 04/01/2018 03/31/2022 NIH R33
Developing the first TPI Df therapeutics 04/01/2021 03/30/2026 NIH R01
High-content screening for TPI Deficiency therapeutics 07/01/2021 06/30/2026 NIH R01